论文部分内容阅读
目的:介绍SELDI-TOF-MS技术预测吉非替尼治疗肺癌疗效观察,探索新的用药指征。方法:应用CM10弱阳离子芯片结合表面增强飞行时间质谱(SELDI-TOF-MS)技术检测9例晚期肺癌患者口服吉非替尼前血清样本的蛋白质谱,口服吉非替尼1个月后,根据实体瘤近期疗效标准分为服药有效组(CR+PR)(4例)和无效组(SD+PD)(5例),利用Biomarker Wizard软件比较各组间的血清蛋白质指纹图谱。结果:有效组与无效组相比有4个蛋白质峰有显著差异性,M/Z分别为4889,1576,1762和8693,与无效组相比,有效组上调的峰为2个,其M/Z为1576和1762,下调的峰为2个,其M/Z为4889和8693结论:SELDI-TOF-MS技术可筛选出预测吉非替尼治疗疗效的相关蛋白质组指纹,此方法捕获的蛋白质组指纹,可作为一种选择用药的新指标。
Objective: To introduce the SELDI-TOF-MS technology to predict the efficacy of gefitinib in the treatment of lung cancer and explore new indications for its use. METHODS: The protein profiles of pre-gefitinib oral samples from 9 patients with advanced lung cancer were detected by CM10 weak cation chip combined with surface-enhanced time of flight mass spectrometry (SELDI-TOF-MS). After 1 month of gefitinib oral administration, Short-term efficacy criteria for solid tumors were divided into two groups: CR + PR (4 cases) and SD + PD (5 cases). Biomarker Wizard software was used to compare serum protein fingerprinting between groups. RESULTS: There were significant differences in four protein peaks between the effective group and the ineffective group with M / Z of 4889, 1576, 1762 and 8693, respectively. Compared with the ineffective group, Z was 1576 and 1762 with 2 down-regulated peaks with M / Z of 4889 and 8693. Conclusion: The SELDI-TOF-MS technique can screen fingerprints of related proteomes that predict the therapeutic effect of gefitinib. The protein captured by this method Group fingerprinting can be used as a new indicator of choice of medication.